Affymetrix, Inc., (Nasdaq: AFFX) today announced that its Chief Medical
Officer, Dr. Rick Hockett, will address the topic of ‘Personalized
Medicine: Planning for the Future’ at a meeting of the American
Association for the Advancement of Science (AAAS) and the Food and Drug
Law Institute (FDLI) on June 1 in Washington, DC.
Dr. Hockett will speak in a panel discussion at 10:15 AM Eastern time on
‘State of the Science: Connecting Biomarkers and Diagnostics.’ The panel
will be chaired by Teri Manolio, Director of the Office of Population
Genomics, at the National Institutes of Health. It will also include
Leigh Anderson, CEO of the Plasma Proteome Institute, and David Borsook,
Co-Director of the Imaging Consortium for Drug Development at McLean
Hospital, Belmont, MA.
“Identifying biomarkers which increase the benefit-to-risk-ratio for
medications allows doctors to provide more meaningful health outcomes
for patients,” said Dr. Hockett. “One of the first examples of
personalized medicine began when doctors utilized glucose measurements
to diagnose diabetes and prescribe insulin. There are still many
challenges ahead to developing similarly effective therapies for more
complex diseases such as cancer. I am looking forward to discussing
these and identifying a path forward with such distinguished colleagues.”
Before joining Affymetrix in March of this year, Dr. Hockett served as
Medical Fellow and the Director of Genomic Medicine at Eli
Lilly. Earlier he spent seven years on staff at the University of
Alabama at Birmingham Hospital, with the positions of Assistant
Professor of Pathology and Head of Clinical Immunology and Molecular
Diagnostics.
This colloquium is free and open to the public. It will be held at the
AAAS Headquarters, 1200 New York Avenue NW, Washington, DC. For more
information visit: http://www.aaas.org/spp/PM/colloquia
About Affymetrix, Inc.
Affymetrix GeneChip® microarray technology is the
industry-standard tool for analyzing complex genetic information. After
inventing microarray technology in the late 1980s, Affymetrix scientists
have been dedicated to developing innovative products that provide
researchers with a more complete view of the genome. These products
continue to accelerate genetic research.
